Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

Specific Antigen ◽

Risk Prostate Cancer ◽

Her 2

Re: Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-risk Prostate Cancer with Rising Prostate-specific Antigen Levels After Primary Local Therapy A Randomized Clinical Trial

European Urology ◽

10.1016/j.eururo.2019.03.031 ◽

2019 ◽

Vol 76 (3) ◽

pp. 405-406

Author(s):

Alexander Kretschmer ◽

Derya Tilki

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

High Risk ◽

Randomized Clinical Trial ◽

Androgen Deprivation Therapy ◽

Specific Antigen ◽

Local Therapy ◽

A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients

Acta Oncologica ◽

10.1080/0284186x.2021.1979246 ◽

2021 ◽

pp. 1-6

Author(s):

Stine E. Petersen ◽

Lise B. Thorsen ◽

Steinbjørn Hansen ◽

Peter M. Petersen ◽

Henriette Lindberg ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase I ◽

Cancer Patients ◽

Pelvic Radiation ◽

Patient Reported ◽

First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology

European Urology Oncology ◽

10.1016/j.euo.2018.07.008 ◽

2018 ◽

Vol 1 (5) ◽

pp. 378-385

Author(s):

Jung Julie Kang ◽

Robert E. Reiter ◽

Michael L. Steinberg ◽

Christopher R. King

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Specific Antigen ◽

Cancer Pathology ◽

Results from a first in man Phase I/II adjuvant Dendritic Cell Vaccine study in high risk prostate cancer patients following radical surgery

Cytotherapy ◽

10.1016/j.jcyt.2017.02.025 ◽

2017 ◽

Vol 19 (5) ◽

pp. S15 ◽

Cited By ~ 1

Author(s):

A.A. Tryggestad ◽

I. Bigalke ◽

K. Axcrona ◽

E. Inderberg ◽

G. Skorstad ◽

...

Keyword(s):

Prostate Cancer ◽

Dendritic Cell ◽

High Risk ◽

Phase I ◽

Cancer Patients ◽

Radical Surgery ◽

Dendritic Cell Vaccine ◽

Cell Vaccine ◽

The role of androgen deprivation therapy in high-risk prostate cancer with Gleason score 8-10 and prostate-specific antigen ≤15 treated with permanent interstitial brachytherapy

Brachytherapy ◽

10.1016/j.brachy.2009.03.147 ◽

2009 ◽

Vol 8 (2) ◽

pp. 165

Author(s):

L. Christine Fang ◽

Gregory S. Merrick ◽

Brian C. Murray ◽

Kent E. Wallner ◽

Wayne M. Butler ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation Therapy ◽

Gleason Score ◽

Specific Antigen ◽

Androgen Deprivation ◽

Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer

Cancer ◽

10.1002/cncr.10673 ◽

2002 ◽

Vol 95 (2) ◽

pp. 275-280 ◽

Cited By ~ 15

Author(s):

Anthony V. D'Amico ◽

Tara Saegaert ◽

Ming-Hui Chen ◽

Andrew A. Renshaw ◽

Daniel George ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Hormonal Therapy ◽

Specific Antigen ◽

Neoadjuvant Hormonal Therapy ◽

Time to disease progression is a predictor of metastasis and mortality in patients with high-risk prostate cancer who achieved undetectable prostate-specific antigen following robot-assisted radical prostatectomy

European Urology Supplements ◽

10.1016/s1569-9056(18)32262-0 ◽

2018 ◽

Vol 17 (2) ◽

pp. e1831

Author(s):

K.C. Koo ◽

D.H. Lee ◽

D.K. Kim ◽

Y.S. Ha ◽

J.W. Kim ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Disease Progression ◽

Specific Antigen ◽

Robot Assisted ◽

The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer

PLoS ONE ◽

10.1371/journal.pone.0218645 ◽

2019 ◽

Vol 14 (11) ◽

pp. e0218645 ◽

Cited By ~ 1

Author(s):

Song Zheng ◽

Shaoqin Jiang ◽

Zhenlin Chen ◽

Zhangcheng Huang ◽

Wenzhen Shi ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Prostate Volume ◽

Specific Antigen ◽

The First Prostate Specific Antigen Value after Androgen Deprivation Therapy Initiation and after Definitive Radiation Therapy Completion As a Biomarker For Disease Relapse and Mortality in Intermediate and High Risk Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2018.07.254 ◽

2018 ◽

Vol 102 (3) ◽

pp. e133

Author(s):

M.A. Patel ◽

M.A. Kollmeier ◽

S. McBride ◽

D. Gorovets ◽

M. Varghese ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Specific Antigen ◽

Disease Relapse ◽

Therapy Initiation ◽

Risk Prostate Cancer ◽

Therapy Completion

Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer

BJU International ◽

10.1111/j.1464-410x.2009.09080.x ◽

2009 ◽

Vol 106 (1) ◽

pp. 86-90 ◽

Cited By ~ 18

Author(s):

Guillaume Ploussard ◽

Laurent Salomon ◽

Yves Allory ◽

Stéphane Terry ◽

Dimitri Vordos ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Specific Antigen ◽

Laparoscopic Radical Prostatectomy ◽

Pathological Findings ◽